Review



chromatin modi cation compound library  (TargetMol)


Bioz Verified Symbol TargetMol is a verified supplier
Bioz Manufacturer Symbol TargetMol manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    TargetMol chromatin modi cation compound library
    Chromatin Modi Cation Compound Library, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/epigenetic+modifications/Chromatin+Modification+Compound+Library/ppr0899171-166-26-31
    Average 94 stars, based on 6 article reviews
    chromatin modi cation compound library - by Bioz Stars, 2026-11
    94/100 stars

    Images

    Related Articles

    Modification:

    Article Title: WTAP-mediated m 6 A methylation of PHF19 facilitates cell cycle progression by remodeling the accessible chromatin landscape in t(8;21) AML.
    Article Snippet: To induce the protein expression of HIF1α, cells were treated with 100 μM CoCl2.6H2O (Sigma-Aldrich, #C8661-25G) for 24 h. Cells treated with 0.1% (v/v) dimethyl sulfoxide (DMSO) served as the vehicle control. .. To test the drug sensitivity of PRC2 histone methyltransferase inhibitors, cells were seeded into 96-well plates and respectively treated with 9 small molecular compounds from a Chromatin Modification Compound Library (Targetmol #L8300) at a concentration of 10 μM for 24–96 h, and then subjected to cell viability evaluation. ..

    Article Title: Integrated CHARGE syndrome models reveal epigenetic modulators of reproductive phenotypes
    Article Snippet: .. For drug testing, 10 μl of each compound, 10 mM in DMSO 100% from the Chromatin Modification Compound Library (TargetMol, Wellesley Hills, MA, USA; cat. L8300) were dissolved in 133μl of M9 buffer 1× ( ) to reach the concentration of 700 μM. .. For drug testing, 10 μl of each compound, 10 mM in DMSO 100% from the Chromatin Modification Compound Library (TargetMol, Wellesley Hills, MA, USA; cat. L8300) were dissolved in 133μl of M9 buffer 1× ( ) to reach the concentration of 700 μM.

    Article Title: Lentiviral delivery of co-packaged Cas9 mRNA and a Vegfa-targeting guide RNA prevents wet age-related macular degeneration in mice.
    Article Snippet: 1Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, China.. 2Department of Ophthalmology, Shanghai General Hospital (Shanghai First People’s Hospital), Shanghai Jiao Tong University School of Medicine, Shanghai, China.. 3Institute of Neuroscience, State Key Laboratory of Neuroscience, Key Laboratory of Primate Neurobiology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China.

    Drug discovery:

    Article Title: WTAP-mediated m 6 A methylation of PHF19 facilitates cell cycle progression by remodeling the accessible chromatin landscape in t(8;21) AML.
    Article Snippet: To induce the protein expression of HIF1α, cells were treated with 100 μM CoCl2.6H2O (Sigma-Aldrich, #C8661-25G) for 24 h. Cells treated with 0.1% (v/v) dimethyl sulfoxide (DMSO) served as the vehicle control. .. To test the drug sensitivity of PRC2 histone methyltransferase inhibitors, cells were seeded into 96-well plates and respectively treated with 9 small molecular compounds from a Chromatin Modification Compound Library (Targetmol #L8300) at a concentration of 10 μM for 24–96 h, and then subjected to cell viability evaluation. ..

    Article Title: Integrated CHARGE syndrome models reveal epigenetic modulators of reproductive phenotypes
    Article Snippet: .. For drug testing, 10 μl of each compound, 10 mM in DMSO 100% from the Chromatin Modification Compound Library (TargetMol, Wellesley Hills, MA, USA; cat. L8300) were dissolved in 133μl of M9 buffer 1× ( ) to reach the concentration of 700 μM. .. For drug testing, 10 μl of each compound, 10 mM in DMSO 100% from the Chromatin Modification Compound Library (TargetMol, Wellesley Hills, MA, USA; cat. L8300) were dissolved in 133μl of M9 buffer 1× ( ) to reach the concentration of 700 μM.

    Article Title: WTAP-mediated m6A methylation of PHF19 facilitates cell cycle progression by remodeling the accessible chromatin landscape in t(8;21) AML
    Article Snippet: .. To test the drug sensitivity of PRC2 histone methyltransferase inhibitors, cells were seeded into 96-well plates and respectively treated with 9 small molecular compounds from a Chromatin Modi cation Compound Library (Targetmol #L8300) at a concentration of 10 μM for 24–96 hours, and then subjected to cell viability evaluation. ..

    Concentration Assay:

    Article Title: WTAP-mediated m 6 A methylation of PHF19 facilitates cell cycle progression by remodeling the accessible chromatin landscape in t(8;21) AML.
    Article Snippet: To induce the protein expression of HIF1α, cells were treated with 100 μM CoCl2.6H2O (Sigma-Aldrich, #C8661-25G) for 24 h. Cells treated with 0.1% (v/v) dimethyl sulfoxide (DMSO) served as the vehicle control. .. To test the drug sensitivity of PRC2 histone methyltransferase inhibitors, cells were seeded into 96-well plates and respectively treated with 9 small molecular compounds from a Chromatin Modification Compound Library (Targetmol #L8300) at a concentration of 10 μM for 24–96 h, and then subjected to cell viability evaluation. ..

    Article Title: Integrated CHARGE syndrome models reveal epigenetic modulators of reproductive phenotypes
    Article Snippet: .. For drug testing, 10 μl of each compound, 10 mM in DMSO 100% from the Chromatin Modification Compound Library (TargetMol, Wellesley Hills, MA, USA; cat. L8300) were dissolved in 133μl of M9 buffer 1× ( ) to reach the concentration of 700 μM. .. For drug testing, 10 μl of each compound, 10 mM in DMSO 100% from the Chromatin Modification Compound Library (TargetMol, Wellesley Hills, MA, USA; cat. L8300) were dissolved in 133μl of M9 buffer 1× ( ) to reach the concentration of 700 μM.

    Article Title: WTAP-mediated m6A methylation of PHF19 facilitates cell cycle progression by remodeling the accessible chromatin landscape in t(8;21) AML
    Article Snippet: .. To test the drug sensitivity of PRC2 histone methyltransferase inhibitors, cells were seeded into 96-well plates and respectively treated with 9 small molecular compounds from a Chromatin Modi cation Compound Library (Targetmol #L8300) at a concentration of 10 μM for 24–96 hours, and then subjected to cell viability evaluation. ..

    Article Title: Lentiviral delivery of co-packaged Cas9 mRNA and a Vegfa-targeting guide RNA prevents wet age-related macular degeneration in mice.
    Article Snippet: 1Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, China.. 2Department of Ophthalmology, Shanghai General Hospital (Shanghai First People’s Hospital), Shanghai Jiao Tong University School of Medicine, Shanghai, China.. 3Institute of Neuroscience, State Key Laboratory of Neuroscience, Key Laboratory of Primate Neurobiology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China.

    other:

    Article Title: IFN-β Pretreatment Alleviates Allogeneic Renal Tubular Epithelial Cell-Induced NK Cell Responses via the IRF7/HLA-E/NKG2A Axis.
    Article Snippet: RESEARCH ARTICLE | DECEMBER 27 2023 IFN-β Pretreatment Alleviates Allogeneic Renal Tubular Epithelial Cell– Induced NK Cell Responses via the IRF7/HLA-E/NKG2A Axis Xing Zhang; ... et.. al J Immunol (2024) 212 (4): 715–722.. https://doi.org/10.4049/jimmunol.2200941 Related Content NKG2A Inhibits Invariant NKT Cell Activation in Hepatic Injury J Immunol (January,2009) Spontaneous interstitial nephritis in kdkd mice.

    Article Title: Single-cell multiomics sequencing reveals the reprogramming defects in embryos generated by round spermatid injection
    Article Snippet: The PCR product was gel-extracted, subcloned into the pClone007 Versatile Simple Vector (TSINGKE, 007VS), and sequenced.

    Sensitivity:

    Article Title: WTAP-mediated m6A methylation of PHF19 facilitates cell cycle progression by remodeling the accessible chromatin landscape in t(8;21) AML
    Article Snippet: .. To test the drug sensitivity of PRC2 histone methyltransferase inhibitors, cells were seeded into 96-well plates and respectively treated with 9 small molecular compounds from a Chromatin Modi cation Compound Library (Targetmol #L8300) at a concentration of 10 μM for 24–96 hours, and then subjected to cell viability evaluation. ..

    96 Well Plates:

    Article Title: WTAP-mediated m6A methylation of PHF19 facilitates cell cycle progression by remodeling the accessible chromatin landscape in t(8;21) AML
    Article Snippet: .. To test the drug sensitivity of PRC2 histone methyltransferase inhibitors, cells were seeded into 96-well plates and respectively treated with 9 small molecular compounds from a Chromatin Modi cation Compound Library (Targetmol #L8300) at a concentration of 10 μM for 24–96 hours, and then subjected to cell viability evaluation. ..

    Histone Deacetylase Assay:

    Article Title: Lentiviral delivery of co-packaged Cas9 mRNA and a Vegfa-targeting guide RNA prevents wet age-related macular degeneration in mice.
    Article Snippet: 1Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, China.. 2Department of Ophthalmology, Shanghai General Hospital (Shanghai First People’s Hospital), Shanghai Jiao Tong University School of Medicine, Shanghai, China.. 3Institute of Neuroscience, State Key Laboratory of Neuroscience, Key Laboratory of Primate Neurobiology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China.

    Transduction:

    Article Title: Lentiviral delivery of co-packaged Cas9 mRNA and a Vegfa-targeting guide RNA prevents wet age-related macular degeneration in mice.
    Article Snippet: 1Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, China.. 2Department of Ophthalmology, Shanghai General Hospital (Shanghai First People’s Hospital), Shanghai Jiao Tong University School of Medicine, Shanghai, China.. 3Institute of Neuroscience, State Key Laboratory of Neuroscience, Key Laboratory of Primate Neurobiology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China.



    Similar Products

    94
    TargetMol epigenetics compound library
    Epigenetics Compound Library, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/epigenetic+modifications/Histone+Modification+Compound+Library/10__1016_slash_j__apsb__2026__06__020-48-1-5
    Average 94 stars, based on 1 article reviews
    epigenetics compound library - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    TargetMol epigenetic targeting
    Epigenetic Targeting, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/epigenetic+modifications/Histone+Modification+Compound+Library/10__1016_slash_j__apsb__2026__05__020-185-0-14
    Average 94 stars, based on 1 article reviews
    epigenetic targeting - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    TargetMol targetmol epigenetic inhibitors
    High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including SGC <t>epigenetic</t> compounds, FDA-approved oncology drugs, and TargetMol epigenetic <t>inhibitors.</t> (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.
    Targetmol Epigenetic Inhibitors, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/epigenetic+modifications/Histone+Modification+Compound+Library/bio_rxiv__64898__2026__04__16__719008-139-10-10
    Average 94 stars, based on 1 article reviews
    targetmol epigenetic inhibitors - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    TargetMol 380 targetmol epigenetic inhibitors
    High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including SGC <t>epigenetic</t> compounds, FDA-approved oncology drugs, and TargetMol epigenetic <t>inhibitors.</t> (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.
    380 Targetmol Epigenetic Inhibitors, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/epigenetic+modifications/Histone+Modification+Compound+Library/bio_rxiv__64898__2026__04__16__719008-78-19-20
    Average 94 stars, based on 1 article reviews
    380 targetmol epigenetic inhibitors - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    TargetMol sgc epigenetic compounds
    High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including <t>SGC</t> <t>epigenetic</t> compounds, FDA-approved oncology drugs, and TargetMol epigenetic inhibitors. (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.
    Sgc Epigenetic Compounds, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/epigenetic+modifications/Histone+Modification+Compound+Library/bio_rxiv__64898__2026__04__16__719008-78-16-20
    Average 94 stars, based on 1 article reviews
    sgc epigenetic compounds - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    86
    Biomark Inc rna epigenetic modifications
    High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including <t>SGC</t> <t>epigenetic</t> compounds, FDA-approved oncology drugs, and TargetMol epigenetic inhibitors. (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.
    Rna Epigenetic Modifications, supplied by Biomark Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/epigenetic+modifications/epigenetic+modifications+rna/pm41928252-984-26-39
    Average 86 stars, based on 1 article reviews
    rna epigenetic modifications - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    86
    Abbott Laboratories epigenetic modifications
    High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including <t>SGC</t> <t>epigenetic</t> compounds, FDA-approved oncology drugs, and TargetMol epigenetic inhibitors. (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.
    Epigenetic Modifications, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/epigenetic+modifications/epigenetic+modifications/pm41866754-363-1-32
    Average 86 stars, based on 1 article reviews
    epigenetic modifications - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    94
    TargetMol epigenetic inhibitors
    High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including <t>SGC</t> <t>epigenetic</t> compounds, FDA-approved oncology drugs, and TargetMol epigenetic inhibitors. (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.
    Epigenetic Inhibitors, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/epigenetic+modifications/Histone+Modification+Compound+Library/pm41713838-53-7-15
    Average 94 stars, based on 1 article reviews
    epigenetic inhibitors - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    90
    Epigenomics ag epigenetic modifications
    High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including <t>SGC</t> <t>epigenetic</t> compounds, FDA-approved oncology drugs, and TargetMol epigenetic inhibitors. (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.
    Epigenetic Modifications, supplied by Epigenomics ag, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/epigenetic+modifications/epigenetic+modifications/pmc12204941-61-11-16
    Average 90 stars, based on 1 article reviews
    epigenetic modifications - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    Image Search Results


    High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including SGC epigenetic compounds, FDA-approved oncology drugs, and TargetMol epigenetic inhibitors. (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.

    Journal: bioRxiv

    Article Title: Acquired resistance to the PRMT5 inhibitor confers collateral sensitivity to MEK inhibition in MTAP-null non-small cell lung cancer

    doi: 10.64898/2026.04.16.719008

    Figure Lengend Snippet: High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including SGC epigenetic compounds, FDA-approved oncology drugs, and TargetMol epigenetic inhibitors. (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.

    Article Snippet: The screening library comprised 619 compounds, including SGC epigenetic compounds, TargetMol epigenetic inhibitors, and FDA-approved oncology drugs ( ).

    Techniques: High Throughput Screening Assay, Drug discovery, Control

    High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including SGC epigenetic compounds, FDA-approved oncology drugs, and TargetMol epigenetic inhibitors. (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.

    Journal: bioRxiv

    Article Title: Acquired resistance to the PRMT5 inhibitor confers collateral sensitivity to MEK inhibition in MTAP-null non-small cell lung cancer

    doi: 10.64898/2026.04.16.719008

    Figure Lengend Snippet: High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including SGC epigenetic compounds, FDA-approved oncology drugs, and TargetMol epigenetic inhibitors. (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.

    Article Snippet: A high-throughput drug screen was performed using a compound library consisting of 619 compounds, including 59 SGC epigenetic compounds, 380 TargetMol epigenetic inhibitors and 180 FDA-approved oncology drugs.

    Techniques: High Throughput Screening Assay, Drug discovery, Control

    High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including SGC epigenetic compounds, FDA-approved oncology drugs, and TargetMol epigenetic inhibitors. (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.

    Journal: bioRxiv

    Article Title: Acquired resistance to the PRMT5 inhibitor confers collateral sensitivity to MEK inhibition in MTAP-null non-small cell lung cancer

    doi: 10.64898/2026.04.16.719008

    Figure Lengend Snippet: High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including SGC epigenetic compounds, FDA-approved oncology drugs, and TargetMol epigenetic inhibitors. (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.

    Article Snippet: A high-throughput drug screen was performed using a compound library consisting of 619 compounds, including 59 SGC epigenetic compounds, 380 TargetMol epigenetic inhibitors and 180 FDA-approved oncology drugs.

    Techniques: High Throughput Screening Assay, Drug discovery, Control